What the STEP 1 extension observed
Wilding and colleagues followed 327 participants after semaglutide and the study’s lifestyle intervention stopped. Over the following year, the former semaglutide group regained about two-thirds of its prior average weight loss. This was an exploratory extension of a trial in adults without diabetes, not a new randomized comparison of stopping strategies. Source: Wilding et al. (2022): STEP 1 trial extension
Recognize the limits
Both medication and lifestyle support ended, so their separate contributions cannot be isolated from this result. A selected extension group does not represent every patient or product. The publication reports industry relationships among authors. The result supports discussing maintenance; it does not prove that every person must follow one lifelong regimen. Source: Wilding et al. (2022): STEP 1 trial extension
Plan transitions before a gap
Ask the prescriber what happens if treatment becomes unaffordable, unavailable or unsuitable. Discuss follow-up, alternative approaches and which health measures to monitor. Do not restart a previous dose after a gap without guidance. If weight changes after stopping, bring that information back into care rather than assuming it means you failed.
Questions to bring to your visit
- What is the maintenance plan?
- What should happen if treatment is interrupted?
- Which follow-up measures would guide a change?
Sources and further reading
- Wilding et al. (2022): STEP 1 trial extensionJournal publication · Original exploratory extension study; DOI 10.1111/dom.14725. Accessed 2026-10-25
This is a patient-facing guide, not an original research publication. Prepared with AI assistance and checked against the linked sources. No clinician review is claimed. General education cannot determine which care is right for you.